R&D gap stymies access to children’s medicines – report

The article focuses on findings from the Access to Medicine Foundation's paediatric analysis. Of the over 1,000 projects analysed from 20 leading pharma companies included in the 2021 Access to Medicine Index, less than 7% are intended for children under 12. 

The piece highlights the game-changing potential of some of the projects in the pharmaceutical pipeline, especially for those in low- and middle-income countries, but emphasises the need for comprehensive access plans to ensure these medicines can reach the children who need them.

Claudia Martinez, programme manager for the Access to Medicine Index, is quoted in the article.

Click to read the full article.